TOP TEN perturbations for 39587_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39587_at
Selected probe(set): 206016_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39587_at (206016_at) across 6674 perturbations tested by GENEVESTIGATOR:

B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)

Relative Expression (log2-ratio):2.9773693
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal B-cell; 20uM)
MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

male infertility study 1 (juvenile; Ad-) / normal testicular lobules tissue (mJS10)

Relative Expression (log2-ratio):2.527381
Number of Samples:2 / 8
Experimental male infertility study 1 (juvenile; Ad-)
Human testicular lobules biopsy samples isolated from prepubescent patients with undescended testes. Testes of these children contained very low level of A-dark (Ad-) spermatogonial cells.
Control normal testicular lobules tissue (mJS10)
Biopsies of human testicular lobules isolated from fertile vasectomized adult men with normal spermatogenesis. Histological analysis classified samples as mJS10 (modified Johnsen score 10).

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample

Relative Expression (log2-ratio):2.4768276
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal B-cell sample
MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

male infertility study 1 (juvenile; Ad+) / normal testicular lobules tissue (mJS10)

Relative Expression (log2-ratio):2.29992
Number of Samples:5 / 8
Experimental male infertility study 1 (juvenile; Ad+)
Human testicular lobules biopsy samples isolated from prepubescent patients with undescended testes. Testes of these children contained typical level of A-dark (Ad+) spermatogonial cells.
Control normal testicular lobules tissue (mJS10)
Biopsies of human testicular lobules isolated from fertile vasectomized adult men with normal spermatogenesis. Histological analysis classified samples as mJS10 (modified Johnsen score 10).

atopic dermatitis study 12 (non-lesional; adults) / atopic dermatitis study 12 (non-lesional; children)

Relative Expression (log2-ratio):2.1972313
Number of Samples:20 / 19
Experimental atopic dermatitis study 12 (non-lesional; adults)
Unaffected skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis.
Control atopic dermatitis study 12 (non-lesional; children)
Unaffected buttock skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All patients had moderate-to-severe disease (SCORAD score: mean, 57.8; range, 33-84) with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded.

brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample

Relative Expression (log2-ratio):-2.1870852
Number of Samples:2 / 3
Experimental brefeldin A study 1 (0.5ug/ml; p53HCT116)
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated p53HCT116 cell sample
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

atopic dermatitis study 12 (lesional; adults) / atopic dermatitis study 12 (lesional; children)

Relative Expression (log2-ratio):2.1458187
Number of Samples:20 / 18
Experimental atopic dermatitis study 12 (lesional; adults)
Lesional skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis.
Control atopic dermatitis study 12 (lesional; children)
Lesional popliteal skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All biopsy specimens were from chronic lesions present for more than 72 hours. All patients had moderate-to-severe disease with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded.

conditioned medium study 1 (HS27a) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):1.9943771
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS27a)
CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

conditioned medium study 1 (HS5) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):1.9777231
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS5)
CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

expO peritoneal cancer study 1 (serous surface papillary carcinoma; metastatic) / expO peritoneal cancer study 1 (papillary serous cystadenocarcinoma; metastatic)

Relative Expression (log2-ratio):1.8613281
Number of Samples:2 / 12
Experimental expO peritoneal cancer study 1 (serous surface papillary carcinoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary serous surface papillary carcinoma of the peritoneum.
Control expO peritoneal cancer study 1 (papillary serous cystadenocarcinoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary papillary serous cystadenocarcinoma of the peritoneum.